Biomedical engineers at Duke University demonstrated a tablet-sized device that can reliably detect multiple COVID-19 antibodies and biomarkers at the same time.
The initial result is test.It can distinguish the antibodies produced in response to SARS-CoV-2 and the other four coronaviruses with 100% accuracy.
Researchers are currently investigating whether easy-to-use, energy-independent point-of-care devices can be used to predict the severity of COVID-19 infection and human immunity to viral variants.
We have also recently shown that the same “D4 test” platform can detect an Ebola infection a day earlier than the reference polymerase chain reaction (PCR) test. Researchers say the technology provides the flexibility to adapt to other current and future diseases. ..
Results will be posted online on June 25 Scientists progress..
“It took six years to develop the D4 test, but when the WHO declared a pandemic, we started compressing all that work into months and using the test as a public health tool. I was able to find a way to do it, ”said Ashtosh Chirkoti, prominent Alan L. Kaganov professor and chairman of Duke’s biomedical engineering department. “Our tests are designed to be both adaptable and real points of service. Clearly, portable, fast, and economical diagnostics are the most useful scenarios. “
This technique relies on a polymer brush coating, which acts as a kind of non-stick coating, preventing anything other than the desired biomarker from sticking to the test slide when wet. The high efficiency of this non-stick shield makes the D4 test extremely sensitive to low level targets. This approach allows researchers to print different molecular traps on different areas of the slide to capture multiple biomarkers at once.
The current iteration of the platform also includes a small patterned tunnel that uses liquid physics to pull samples through channels without the need for electricity. With a drop of blood and a drop of biomolecular lubricant, the test runs autonomously in just a few minutes and can be read by a detector the size of an extra thick iPad.
“The detector is battery powered and does not require any power to be tested. So you can put everything in your backpack and actually test it at the point of care with minimal resources, ”said Jason Liu, Ph.D. D. Students working in the Chilkoti laboratory who designed and manufactured the detector.
In the present study, researchers use a D4 test to detect and quantify antibodies produced against three parts of the COVID-19 virus: the spike protein subunit, the binding domain within the spike capture protein cellular. Tested the ability of. A core protein that packs viral RNA. The test found antibodies in the 31 patients tested for severe cases of COVID-19 two weeks later. In addition, 41 samples from healthy individuals before the start of the pandemic and 18 samples from four other individuals infected with the coronavirus in high circulation had no false positives. I reported.
With a pandemic and hundreds of other COVID-19 antibody tests under development in the United States, researchers believe this particular test is unlikely to be rolled out in large numbers. However, they claim that the platform’s proven accuracy and flexibility makes it a good candidate for the development of other types of tests and use in future outbreaks.
For example, the platform could test whether people are immune to the different strains of COVID-19 that continue to emerge.
“People are wondering if they are protected against the newer variants of COVID-19, and our test may answer some of them,” said Jake Hegetad, PhD. I am. A student working at the Chilkoti lab who developed a test chip. “We believe that our platform should be able to distinguish whether we have antibodies capable of neutralizing the new mutants of concern, or if these antibodies do not protect against the new mutants. I go. “
Researchers are also working on a platform to test multiple prognostic markers for COVID-19, which can be combined to show whether a patient is likely to suffer from serious illness. I go.
“As platform builders, we’re working to show how we can easily modify this technology to do a lot of things,” said graduate student David Kinnamon, who developed the liquid handling system for testing. I am. “We have shown that this unique platform can serve as a diagnostic, assess the immune response after infection and predict disease outcome. Everything can be at the same time. Many tests that can do it. I do not know.”
“And all of this can be done on a very user-friendly and portable platform,” Heggestad explains. “Doing all of this in a centralized facility like Duke is one thing, except you can perform large-scale testing and get great, sensitive results in remote locations around the world. That’s it. ”
Biomedical engineers use rapid testing platform to see if they can catch COVID-19
JT Heggestad et al. , “Multiplexed Quantitative Serologic Profiling of COVID-19 from Blood by Point-of-Care Test”. Scientists progress (2021). Advances.sciencemag.org/lookup… .1126 / sciadv.abg4901
Duke University School of Nursing
Quote: The test distinguishes SARS-CoV-2 from other coronaviruses with 100% accuracy (2021, June 25). Obtained from https://medicalxpress.com/news/2021-06-distinguishes-sars-cov-coronaviruses-accuracy on June 25, 2021. html
This document is subject to copyright. No part may be reproduced without written permission, except for fair dealings for the purposes of personal investigation or research. The content is provided for informational purposes only.
Test distinguishes SARS-CoV-2 from other coronaviruses with 100% accuracy Source link Test distinguishes SARS-CoV-2 from other coronaviruses with 100% accuracy